Company intelligence / Profile preview

Fairbanks Pharmaceuticals

Concord, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Fairbanks Pharmaceuticals was a biotechnology company focused on developing transformative therapies for diabetes by addressing the underlying cause of the disease. Founded in 2014, the company's research centered on the restoration of insulin-producing pancreatic beta cells through the neutralization of follistatin-related protein 3 (FSTL3). Its lead program, FP-101, was a selective monoclonal antibody designed to block FSTL3 from binding to activin and other ligands, thereby promoting beta cell regeneration and transdifferentiation. The company ceased operations in December 2021 following the unexpected passing of its co-founder and CEO, Dr. Alan Schneyer.

Therapeutic areas: Endocrinology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Fairbanks Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fairbanks Pharmaceuticals.

Explore the full profile